Benxi City To Shape Pharmaceutical Valley In Northern China
This article was originally published in PharmAsia News
Benxi city will construct a new eco-town of 60 square kilometers located in the middle of Benxi and Shenyang, of which 23 square kilometers is earmarked as Liaoning (Benxi) biology and pharmaceutical high-tech industry base. Targeted to be an advanced world-class pharmaceutical valley in northern China, a 63 km corridor will be built to house the industry. Benxi aims to attract 200 projects to the base within one year and realize annual revenue of RMB 100 billion ($14.64 billion) by 2012. As of Aug. 5, 33 domestic and overseas pharmaceutical and R&D firms have invested fixed assets reaching RMB 5 billion. The high-tech industry base boasts several advantages: (1) abundant pharmaceutical resources; (2) preferential and incentive policies; (3) talented manpower; (4) technology support; and (5) financial assistance. (Click here for more - Chinese Language)
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.